Article
Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2025
Han Baohui, Liu Jie, Wu Lin, Zhao Yanqiu, Zhang Wei, Chen Bolin, He Jianbo, Shi Jianhua, Liu Yanqing, Zhang Zhe, Chen Xiugui, Wu Yusheng
Abstract excerpt
INTRODUCTION: This phase 1 study evaluated the safety, pharmacokinetics, and preliminary efficacy of TY-9591 (asandeutertinib), a deuterated osimertinib derivative. METHODS: Patients with advanced EGFR-mutated (most commonly exon 19 deletions or L858R) NSCLC were enrolled. In the dose-escalation phase, TY-9591 was administered from 20 to 200 mg once daily to assess dose-limiting toxicities and the maximum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.